CoChat
Sign Up
Cited by 54Immunotherapy and Immune ResponsesHepatitis C virus researchvaccines and immunoinformatics approaches

The DOI matches its Crossref record; the references it cites are not checked yet.

A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection

Open access
Chua, Brendon Y., Eriksson, Emily M., Brown, Lorena E., Zeng, Weiguang, Gowans, Eric J., Torresi, Joseph, Jackson, David C.·2008·Vaccine
DOI 10.1016/j.vaccine.2008.03.032PMC PMC4526279
Open this paper in CoChat — free account

Abstract

Effective CD8(+) T cell responses have been induced using totally synthetic self-adjuvanting lipopeptides containing the dipalmitoyl-S-glyceryl cysteine lipid moiety, which is a ligand for Toll-like receptor 2 (TLR2) on dendritic cells (DC). In this study, we evaluated the use of lipopeptide vaccine candidates containing HLA-A2-restricted epitopes for DC-based immunotherapy of HCV infection. Lipopeptides were able to induce specific CD8(+) T cell responses in HLA-A2 transgenic mice and consistently activated human monocyte-derived DC from both healthy individuals and HCV infected patients. Lipopeptide-pulsed human DC were also found to secrete the pro-inflammatory cytokine IL-12p70 and were able to activate antigen-specific IFN-gamma production by autologous CD8(+) T cells obtained from a hepatitis C patient. These results show that DC from HCV patients can be matured and antigen loaded with TLR2-targeting lipopeptides for effective presentation of CD8(+) T cell epitopes; the use of autologous lipopeptide-pulsed DC or direct lipopeptide vaccination may be successful approaches for the priming or boosting of anti-HCV CD8(+) T cell responses to aid in the clearance of the virus in chronically infected individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2008.03.032

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 45 · Cited by 54

Research works printed but not linked: 45

  1. Alter, 2000, Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome, Semin Liver Dis, 20, 17, 10.1055/s-2000-9505 · DOI
  2. Shindo, 1992, Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon, Hepatology, 15, 1013, 10.1002/hep.1840150607 · DOI
  3. McHutchison, 1998, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group, N Engl J Med, 339, 1485, 10.1056/NEJM199811193392101 · DOI
  4. Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 · DOI
  5. Urbani, 2006, Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses, Hepatology, 44, 126, 10.1002/hep.21242 · DOI
  6. Smyk-Pearson, 2006, Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design, J Infect Dis, 194, 454, 10.1086/505714 · DOI
  7. Schulze zur Wiesch, 2005, Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes, J Immunol, 175, 3603, 10.4049/jimmunol.175.6.3603 · DOI
  8. Cox, 2005, Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C, Hepatology, 42, 104, 10.1002/hep.20749 · DOI
  9. Wedemeyer, 2002, Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection, J Immunol, 169, 3447, 10.4049/jimmunol.169.6.3447 · DOI
  10. Auffermann-Gretzinger, 2001, Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection, Blood, 97, 3171, 10.1182/blood.V97.10.3171 · DOI
  11. Kanto, 1999, Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals, J Immunol, 162, 5584, 10.4049/jimmunol.162.9.5584 · DOI
  12. Bain, 2001, Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection, Gastroenterology, 120, 512, 10.1053/gast.2001.21212 · DOI
  13. Kakumu, 2000, Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection, J Gastroenterol Hepatol, 15, 431, 10.1046/j.1440-1746.2000.02161.x · DOI
  14. Tsubouchi, 2004, Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection, J Gastroenterol, 39, 754, 10.1007/s00535-003-1385-3 · DOI
  15. Murakami, 2004, Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C, Clin Exp Immunol, 137, 559, 10.1111/j.1365-2249.2004.02550.x · DOI
  16. Ulsenheimer, 2005, Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection, Hepatology, 41, 643, 10.1002/hep.20592 · DOI
  17. Kanto, 2006, Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels, Intervirology, 49, 58, 10.1159/000087264 · DOI
  18. Pachiadakis, 2005, Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?, Lancet Infect Dis, 5, 296, 10.1016/S1473-3099(05)70114-6 · DOI
  19. Sarobe, 2002, Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins, J Virol, 76, 5062, 10.1128/JVI.76.10.5062-5070.2002 · DOI
  20. Kim, 2002, Identification of hepatitis C virus core domain inducing suppression of allostimulatory capacity of dendritic cells, Arch Pharm Res, 25, 364, 10.1007/BF02976640 · DOI
  21. Dolganiuc, 2003, Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation, J Immunol, 170, 5615, 10.4049/jimmunol.170.11.5615 · DOI
  22. Deliyannis, 2006, Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza, Eur J Immunol, 36, 770, 10.1002/eji.200535217 · DOI
  23. Zeng, 2002, Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines, J Immunol, 169, 4905, 10.4049/jimmunol.169.9.4905 · DOI
  24. Jackson, 2004, A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses, Proc Natl Acad Sci USA, 101, 15440, 10.1073/pnas.0406740101 · DOI · Paper page
  25. Muhlradt, 1997, Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration, J Exp Med, 185, 1951, 10.1084/jem.185.11.1951 · DOI
  26. Lau, 2006, Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines, Int Immunol, 18, 1801, 10.1093/intimm/dxl114 · DOI
  27. Chua, 2007, Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups, Vaccine, 25, 92, 10.1016/j.vaccine.2006.07.012 · DOI
  28. Chua, 2003, Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus, Immunol Cell Biol, 81, 67, 10.1046/j.1440-1711.2003.01133.x · DOI
  29. Jackson, 2005, Dendritic cell immunotherapy of hepatitis C virus infection: toxicology of lipopeptide-loaded dendritic cells, International Journal of Peptide Research and Therapeutics, 11, 223, 10.1007/s10989-005-9270-y · DOI
  30. Ghosh, 2001, Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus, Immunology, 104, 58, 10.1046/j.0019-2805.2001.01271.x · DOI
  31. Lauer, 2002, Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities, J Virol, 76, 6104, 10.1128/JVI.76.12.6104-6113.2002 · DOI
  32. Takaki, 2000, Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C, Nat Med, 6, 578, 10.1038/75063 · DOI
  33. Lechner, 2000, Analysis of successful immune responses in persons infected with hepatitis C virus, J Exp Med, 191, 1499, 10.1084/jem.191.9.1499 · DOI
  34. Chen, 1989, Direct binding of influenza peptides to class I HLA molecules, Nature, 337, 743, 10.1038/337743a0 · DOI
  35. Robertson, 2000, DO11. 10 and OT-II T cells recognize a C-terminal ovalbumin 323–339 epitope, J Immunol, 164, 4706, 10.4049/jimmunol.164.9.4706 · DOI
  36. Deliyannis, 2002, Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus, J Virol, 76, 4212, 10.1128/JVI.76.9.4212-4221.2002 · DOI
  37. Dolganiuc, 2006, Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection, World J Gastroenterol, 12, 1198, 10.3748/wjg.v12.i8.1198 · DOI
  38. Spangenberg, 2005, Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection, Hepatology, 42, 828, 10.1002/hep.20856 · DOI
  39. McIlroy, 2003, Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact, Cancer Immunol Immunother, 52, 583, 10.1007/s00262-003-0414-7 · DOI
  40. Dolganiuc, 2004, Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation, Gastroenterology, 127, 1513, 10.1053/j.gastro.2004.08.067 · DOI
  41. Yakushijin, 2006, Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection, Hepatol Res, 34, 156, 10.1016/j.hepres.2005.12.010 · DOI
  42. Visintin, 2001, Regulation of Toll-like receptors in human monocytes and dendritic cells, J Immunol, 166, 249, 10.4049/jimmunol.166.1.249 · DOI
  43. Uronen-Hansson, 2004, Immunology, 111, 173, 10.1111/j.0019-2805.2003.01803.x · DOI
  44. Auron, 1998, The interleukin 1 receptor: ligand interactions and signal transduction, Cytokine Growth Factor Rev, 9, 221, 10.1016/S1359-6101(98)00018-5 · DOI
  45. Schjetne, 2003, Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target, J Immunol, 171, 32, 10.4049/jimmunol.171.1.32 · DOI

Metadata

Authors
Chua, B. Y., Eriksson, E. M., Brown, L. E., Zeng, W., Gowans, E. J., Torresi, J., & Jackson, D. C.
Affiliations
  • The University of Melbourne (AU)
  • Burnet Institute (AU)
  • The Royal Melbourne Hospital (AU)
Corresponding author
Jackson, David C.
ORCID
Venue
Vaccine
Publisher
Elsevier BV
Published
2008-09
Volume
26
Issue
37
Pages
4866-4875
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2008.03.032
PMC
PMC4526279
OpenAlex
W2034915595
Cited by
54
References
45
Citations by year
2026: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 4 · 2014: 7 · 2013: 2 · 2012: 7
FWCI
2.23
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
National Institute of Allergy and Infectious Diseases (R01AI054459)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
hepatitis C virus, lipopeptide vaccine, self-adjuvanting vaccine, TLR2, dendritic cells, CD8+ T cell responses, HLA-A2-restricted epitopes, IL-12, interferon-gamma, chronic hepatitis C, monocyte-derived dendritic cells
MeSH terms
Animals, Cells, Cultured, Dendritic Cells, Hepatitis C, Humans, Interferon-gamma, Lipoproteins, Mice, Inbred C57BL, Mice, Transgenic, Viral Hepatitis Vaccines, HLA-A2 Antigen, CD8-Positive T-Lymphocytes, Interleukin-12, Vaccines, Subunit, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. https://app.cochat.ai/papers/10.1016/j.vaccine.2008.03.032
The paper
Chua, B. Y., Eriksson, E. M., Brown, L. E., Zeng, W., Gowans, E. J., Torresi, J., & Jackson, D. C. (2008). A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine. https://doi.org/10.1016/j.vaccine.2008.03.032